NEW YORK, Sept 3 (Reuters) - Drug maker Wyeth
(nyse: WYE - news - people) has
sent a two-page letter to doctors to warn them that its Effexor
antidepressant may be more likely to cause children to consider
suicide, the Wall Street Journal reported on Wednesday.
The company said it decided to notify doctors as a
precaution, the paper reported.
"It's important safety information, and we thought it was
important enough to provide in a letter to health-care
physicians," Wyeth spokesman Douglas Petkus told the Journal. A
Wyeth spokesperson was not immediately available to comment to
Reuters.
The warning comes two months after the U.S. Food and Drug
Administration warned about GlaxoSmithKline Plc's <GSK.L> Paxil
use for children under 18 amid data suggesting it may lead to
suicidal thoughts, said the paper. Petkus said Wyeth's warning
was not related to the Paxil worries, according to the Journal.
Wyeth told the newspaper the data that prompted the warning
letter were from several studies and that some were continuing,
though it did not specify how many studies it had conducted on
the drug and children, or how recent the studies were.
As of July, Effexor was Wyeth's best-selling product. The
drug, which regulates two brain messenger chemicals, is
becoming increasingly popular for patients who have failed to
benefit from older therapies such as Eli Lilly & Co.'s
(nyse: LLY - news - people)
Prozac.
Effexor, which has not been approved for children, has been
shown to be more effective than many standard depression
treatments although it has been linked to more side effects.
Market data provided by Reuters. Disclaimer
Stock quotes are delayed at least 15 minutes for Nasdaq, at least 20 minutes for NYSE/AMEX.
U.S. indexes are delayed at least 15 minutes with the exception of S&P 500 which is real-time.
Forbes 40 Index powered by Telemet.
News may include latest headlines from Reuters.
